In studies in the female rat, it has been shown that luteinising hormone-releasing hormone (LH-RH) agonists can suppress ovarian activity reducing circulating levels of oestradiol and thus producing a diminution in size of oestrogen-dependent target tissues . Such effects in animals are accompanied by a reduction in size of oestrogen receptor positive dimethylbenzanthracine (DMBA) induced mammary tumours .
Recent clinical studies in premenopausal patients with metastatic breast cancer have produced encouraging results when one such agent (Buserelin, Hoe 766) was used alone and in combination with the anti-oestrogen Tamoxifen. In this study the combination of LH-RH agonist with Tamoxifen was not recommended due to the observation that unpredictable endocrinological responses, overriding the LH-RH induced hypothalamic-pituitary suppression, occurred when these two agents were combined (Klijn, 1984) .
Oophorectomy has become the mainstay of treatment for premenopausal advanced breast cancer since its introduction at the end of the last century. This treatment has the disadvantage that only a minority of patients will respond (Kennedy et al., 1964) (British Breast Group, 1974) . In the first 27 patients showing disease progression on Zoladex surgical oophorectomy was routinely performed in all cases fit for this procedure (n = 26). Patients were reviewed at monthly intervals and routine haematological tests were repeated at each attendance. Skeletal surveys were repeated at three monthly intervals or more frequently if clinically indicated. 2-hormones decreased and were associated with an eventual fall in circulating concentrations of both oestradiol and progesterone in all but two patients (Figure 2 ). With the exception of these two patients, suppression of both pituitary and ovarian hormones was maintained during active therapy with Zoladex. The levels of oestradiol and progesterone found in patients with complete ovarian suppression were equivalent to those seen in either oophorectomised or postmenopausal patients with advanced breast cancer.
Results

Endocrinological
In the two patients with recurrent peaks of oestradiol basal levels of cirulating LH, FSH and progesterone were maintained throughout therapy (Figure 3 ).
No differences in endocrine response were observed between patients receiving doses of 500 or 1000pg daily (not illustrated).
In those patients commencing treatment in the follicular phase of the cycle (n = 12) castrate levels of serum oestradiol and progesterone were attained in 9 patients after one month's therapy. All 9 patients commencing treatment in the luteal phase showed some evidence of cyclical oestradiol production during the second month of treatment before castrate levels were achieved. These oestradiol peaks were, however, suppressed when compared with the mid cycle oestradiol levels found in control patients. The initiation of daily treatment in the luteal phase of the menstrual cycle resulted in a prolongation of the time necessary to achieve complete ovarian suppression, as has been suggested in other clinical studies (Klijn, 1984) . This disadvantage may have clinical implications in rapidly progressing disease.
The explanation for the inability of the LH-RH agonist to achieve complete ovarian suppression in the five patients refractory to the dosage used is not at present clear. Two patients administered their own daily subcutaneous therapy but were observed to be competent at this technique. In the remaining three patients the monthly depot formulation was administered by one author in the outpatient clinic. The failure of the LH-RH agonist did not appear to be related to either premenopausal age or body weight. In all five patients serum progesterone was suppressed to basal levels on continued treatment, an indication that anovulation had occurred.
It is of interest that one patient with incomplete ovarian suppression showed evidence of an early response to treatment in bone metastases after three months therapy, raising the possibility of a direct antitumour effect mediated by the LH-RH agonist. (Harvey et al., 1981) . An alternative explanation is that complete ovarian suppression may not be necessary to achieve objective remissions in all cases. Four patients responded to oophorectomy without an apparent previous response to Zoladex. One of these patients, with lung metastases, was refractory to the dosage of the LH-RH agonist administered with serum oestradiol continuing to peak after six months therapy. This patient remained asymptomatic throughout treatment with Zoladex. The remaining three patients with bone metastases had received treatment for a maximum of only 12 weeks. The clinical responses in all patients were assessed strictly and at short intervals and so with continued therapy a response may have occurred with the use of the LH-RH agonist alone in these three patients. A retrospective review of the X-rays in two of the three patients responding to oophorectomy would suggest to the authors that a mis-classification of disease progression on Zoladex may have occurred as early signs of sclerosis were present in lytic metastases at the time of oophorectomy. Certainly their hormone profiles were comparable with oophorectomised patients.
The response rate to Zoladex of 31% is comparable to our previous experience using surgical oophorectomy and is lower than other reported series as our criteria exclude short remissions of less than six months duration.
The time course to response on Zoladex was similar to that found after surgical oophorectomy in all patients with stage III disease as was the case in those patients with bone metastases. However, in the latter situation objective responses are difficult to assess during the early stages of treatment. The side effects relating to therapy were minimal and all patients tolerated treatment well.
Although patient numbers are small, it appears that the absence of the oestrogen receptor in the primary tumour is predictive of a failure to respond to the administration of Zoladex.
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